Award
NIH Reporter #3U01NS110772-05S2
FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
Recipient
National Institute of Neurological Disorders and Stroke
Award Amount
$72,275.00
Ceiling
$72,275.00
Awarded
February 28, 2026
Identifier
3U01NS110772-05S2
Award for the FASTEST Trial to test recombinant Factor VIIa for acute hemorrhagic stroke treatment within two hours of onset, aiming to improve patient outcomes at 90 days.
Description
The project involves testing recombinant Factor VIIa (rFVIIa) within two hours of stroke onset to improve outcomes measured by the modified Rankin Scale at 90 days. The study includes multiple international sites and uses exception from informed consent and mobile stroke units to minimize time to treatment. Primary safety outcomes include ischemic events within 4 days, and the primary efficacy outcome is the ordinal distribution of the mRS at 90 days.